Describing the patient experience of acute myeloid leukemia treatment in the era of novel therapies: interim results of a longitudinal patient-reported outcomes study

Authors: Nia M. Mitchell¹, Susan C. Locke², Kris W. Herring², Aaron Galaznik³, Debra Wujcik³, Thomas W. LeBlanc^2,4

¹Duke University School of Medicine, ²Duke Cancer Institute, ³Carevive Systems Inc., ⁴Division of Hematologic Malignancies and Cellular Therapy, Dept. of Medicine, Duke University School of Medicine

Background

• Lack of real-world data on patient experience of acute myeloid leukemia (AML) treatment since advent of novel therapies
• Increased utility of routine symptom monitoring using patient-reported outcome measures (PROMs)
• Prospective observational study using Patient Reported Outcomes mobile platform (PROmpt^®)—facilitates reporting of symptoms and level of severity (none, mild, moderate, severe, or very severe) to healthcare team via weekly surveys while on treatment

Methods

• Enrolled patients with AML treated at Duke to use the PROmpt® system between 1/1/2022–4/19/2023
• Analyzed reported symptoms over 12-week period using descriptive statistics, with a focus on moderate to very severe (Mod-VS) symptoms in patients undergoing low-intensity vs. high-intensity treatment regimens

Results

• Top 5 Mod-VS symptoms by no. responses: fatigue, anxiety, decreased appetite, muscle pain, and mouth/throat sores
• Low-intensity = higher rates of Mod-VS fatigue, anxiety, and muscle pain than high-intensity group
• Low-intensity = longitudinally, Mod-VS fatigue remained high and muscle pain increased over time; High-intensity = fatigue and muscle pain decreased over time

Future Directions

• Enrollment ongoing for continued longitudinal data analysis
• Evaluate for trends in symptom reporting based on genetic-risk category
• Standardize survey administration to onset of AML diagnosis and treatment

Click image above to enlarge